This tutorial will help you find optimal settings for your hardware and network as well as give you some pointers to troubleshoot common configuration issues. You ...

Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s most powerful version control tools is within ...

Windows 11 is available for download worldwide. Microsoft has released it as a free upgrade, which means you do not need to pay to upgrade your computer to Windows 11. It is available for free ...

The investigation concerns whether AlloVir and certain of its officers and/or directors have engaged in corporate wrongdoing. We represent investors in class actions on a contingency fee basis. That ...

What is the current share price of AlloVir Inc (ALVR)? AlloVir Inc's (ALVR) current share price is $9.28. This constitutes a price movement of 2,013.41% when compared to the share price 7 days ago and ...

AlloVir, Inc. (NASDAQ:ALVR), a biotechnology company specializing in biological products, announced today that it has completed a reverse stock split of its common stock at a 1-for-23 ratio. The move ...

In a recent development, AlloVir, Inc. (NASDAQ:ALVR), a company specializing in biological products currently trading at $0.45 per share, received approval from its shareholders for a reverse stock ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration. Kalaris is a clinical-stage biopharmaceutical company ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, Inc. (the “Company”) (NasdaqCM: ...

Shares of AlloVir (NASDAQ:ALVR) lost ~18% in the premarket on Friday after the cell therapy developer announced an all-stock merger agreement with clinical-stage biopharmaceutical company Kalaris ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders.